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Hydroxyurea for sickle-cell anaemia in Africa: mind the gap
An estimated 305 800 newborn babies have sickle cell 
anemia, and about two-thirds of these babies are born 
in Africa.1 The burden of disease is expected to rise as 
a result of improved survival in high-prevalence low-
income and middle-income countries.1 Since the ﬁ rst 
clinical description of sickle-cell anaemia more than 
100 years ago, only one drug, hydroxyurea, has been 
shown to have proven eﬃ  cacy for amelioration of 
symptoms. Human stem-cell transplantation remains 
the only cure but is not available in many developing 
countries where the burden of disease is highest. 
Attention must therefore focus on the use of the 
relatively more accessible hydroxyurea. However, a few 
critical questions remain about the applicability of this 
simple regimen in low-resource, high-burden settings. 
Evidence suggests that widespread implementation of 
hydroxyurea for the management of sickle-cell anaemia 
in these settings might be a leap in the dark.
In November, 2014, the US National Heart, Lung, and 
Blood Institute announced the end of a hydroxyurea 
eﬃ  cacy trial2 because of unequivocal results of eﬃ  cacy 
in children. The TWiTCH2 (Transcranial doppler With 
Transfusions Changing to Hydroxyurea) study was a 
clinical phase 3 randomised trial at 25 medical centres 
in the USA and Canada that compared monthly 
erythrocyte transfusions (standard therapy) with 
daily hydroxyurea (the alternative) for 121 children 
between 4–16 years of age with sickle-cell anaemia and 
abnormally elevated transcranial doppler velocities, 
and thus at high risk of stroke. Follow-up was originally 
scheduled for 24 months, but the study was terminated 
after only half the children completed the treatment 
phase owing to overwhelming evidence of beneﬁ t in the 
hydroxyurea-treated group.
In a previous multicentre, randomised, double-blind, 
placebo-controlled trial of hydroxyurea in infants and 
young children, Wang and colleagues3 assessed the 
eﬀ ect of a ﬁ xed dose (20 mg/kg) of hydroxyurea in 
children aged 9–18 months with haemoglobin SS or 
haemoglobin Sβ(0)thalassaemia. The investigators 
reported clinical beneﬁ ts of hydroxyurea, including 
lower rates of pain and dactylitis, admission to 
hospital, and transfusion. However, beneﬁ ts on renal, 
splenic, and neurological function were inconclusive. 
Mild-to-moderate neutropenia was found, but 
there were no associated increase in infections. In a 
subgroup of children, naive and memory T-cell subsets 
and antibody responses to pneumococcal, measles, 
mumps, and rubella vaccines were measured.4 The 
hydroxyurea-treated group had signiﬁ cantly lower total 
CD4 lymphocyte and memory T-cell count than did 
the control group. Although antibody concentrations 
between the two groups were equivalent at study 
exit, it took longer to reach an antibody peak in the 
hydroxyurea-treated group. The practical implication 
of this ﬁ nding in measles-endemic settings with 
suboptimum immunisation coverage is unknown. 
Clearly, this scenario could pose a public health concern 
in the event of disease outbreaks, such as is often the 
case with measles in most developing countries.
Undoubtedly, hydroxyurea has a huge potential 
for improving the quality of lives of people aﬀ ected 
by sickle-cell anaemia in settings where frequent 
and probably unsafe blood transfusions are the 
current standard of care. However, attention needs 
to be directed towards the potential adverse eﬀ ects 
of hydroxyurea in such settings. The studies2,3 from 
developed countries assessed patients in a controlled 
setting with optimum preventive care and used the 
liquid formulation of hydroxyurea in infants and 
children. The availability and stability of this formulation 
in low-resource countries could be a challenge.
A number of centres in Africa and individual patients 
have already started to use generic or branded 
hydroxyurea tablets. Yet the safety of hydroxyurea 
in Africa, where preventive care is poor and the risk 
of infection is very high, has not been assessed. The 
immunosuppressive activity of hydroxyurea suggests 
that long-term use might predispose people to 
increased infection risk. One could also argue that an 
optimum dose to ameliorate the complex manifestation 
of sickle-cell anaemia might culminate in protection 
from infection, but there are currently no safety data 
from Africa.
For optimum beneﬁ ts, the recommendation is to 
aim for the maximum tolerable dose of hydroxyurea.5 
In view of the extreme phenotypic heterogeneity of 
sickle-cell disease, high infectious-disease burden, and 
poor immunisation practices, the dose of hydroxyurea 
needed to achieve optimum clinical beneﬁ t should be 
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approached with care. Thus, as a minimum, controlled 
phase 3 studies of hydroxyurea in Africa are needed to 
establish its safety in this setting, and prolonged active 
surveillance should be maintained to ensure that the 
teratogenic and genotoxic properties of hydroxyurea do 
not cause delayed complications.
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